PLRX

$1.34+0.03 (+2.29%)

Market OpenAs of Mar 17, 4:53 PM UTC

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.34
Potential Upside
5%
Whystock Fair Value$1.41
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecul...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$82.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.28
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-61.55%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
11.72

Recent News

MarketBeat
Mar 1, 2026

Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference

Pliant Therapeutics (NASDAQ:PLRX) used its presentation at Oppenheimer’s 36th Annual Healthcare Conference to outline its strategic transition toward oncology following the discontinuation of its fibrosis efforts. Chief Executive Officer Bernard Coulie and Chief Financial Officer Keith Cummings high

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Oct 17, 2025

3 Promising Penny Stocks With Market Caps Under $500M

As the U.S. stock market faces volatility with regional bank shares plummeting and bond yields hitting lows, investors are increasingly on the lookout for alternative opportunities. Penny stocks, though often overlooked and considered a relic of past trading days, remain relevant as they can offer surprising value in today's market landscape. When these smaller or newer companies are supported by strong financial health, they hold potential for significant returns; here we explore three such...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
The Fly
Oct 10, 2025

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

Align downgraded, NetEase upgraded: Wall Street's top analyst calls

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Sep 8, 2025

Penny Stocks To Watch With Market Caps Under $700M

As the U.S. stock market inches higher amid hopes for interest rate cuts, investors are closely monitoring economic indicators that could influence future Federal Reserve decisions. In this context, penny stocks—typically smaller or newer companies—remain a relevant investment area for those seeking unique opportunities outside the mainstream indices. While the term "penny stocks" might seem outdated, these investments can still offer significant value when backed by strong financials and...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jul 15, 2025

3 Promising Penny Stocks With Market Caps Under $200M

Major indexes in the United States are experiencing mixed performances, with tech stocks rallying and bank stocks sliding following recent inflation data. In this context, penny stocks remain a compelling area of interest for investors looking for potential growth opportunities. Although the term 'penny stocks' may seem outdated, these smaller or newer companies can offer significant value when backed by strong financials. Let's explore several such penny stocks that stand out for their...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.